Bruker (BRKR) has an average rating of overweight and mean price target of $51.58, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $56.35, Change: $-2.09, Percent Change: -3.58%
Johnson Controls International (JCI) is undergoing an operational turnaround supported by improvements in its business system and stronger demand visibility across data center and mission-critical end markets, RBC Capital said in a Monday note.The analysts said Johnson Controls has increased its long-term organic revenue growth outlook to high single digits from mid-single digits, driven by accelerating data center demand, which is expected to grow from about 12% of revenue to roughly one-third within five years amid AI infrastructure expansion.RBC highlighted improved financial targets, including about 30% incremental margins and free cash flow conversion of 95% to 100%, driven by efficiency gains from the company's early-stage rollout of its lean business system across manufacturing sites.The firm cautioned that the transformation remains a multi-year effort with execution risk as the system scales globally. It added that while near-term momentum is improving, the durability of demand and long-term margin expansion will remain key areas for investors to monitor, according to the report.RBC maintained its sector perform rating on the stock with a price target of $154.Shares of Johnson Controls were up 5.8% in Tuesday trading.Price: $141.55, Change: $+7.64, Percent Change: +5.71%
BeOne Medicines (ONC) reported encouraging data from three solid tumor programs, strengthening confidence in its competitive potential and long-term growth, RBC Capital Markets said in a note Tuesday.The company on Monday presented "promising" data on a CDK4 inhibitor for breast cancer, a GPC3-4-1BB bispecific antibody for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer.Analyst Leonid Timashev said each therapy appears to be delivering on its promised profile, with potential safety or efficacy advantages that could support best-in-class positioning or at least strong competitiveness over the coming years.Although investors have generally been skeptical of BeOne Medicines' solid tumor portfolio, RBC believes the building blocks for success are becoming increasingly visible. As a result, the firm now estimates that the company could generate up to $4.8 billion in solid tumor sales by 2035."While more data, and in some cases, optimization is still needed, we think the company's commitment to phase 3 trials and initial data is worth paying attention to," the analyst added.RBC raised its price target on BeOne Medicines to $436 from $425 while keeping its outperform rating.Price: $276.76, Change: $-2.92, Percent Change: -1.04%
President Donald Trump signed a proclamation on Tuesday lowering the tariffs on agricultural equipment and certain other equipment to 15% from 25%, the White House said.Additionally, the existing category of industrial equipment subject to a 15% tariff was expanded to include mobile industrial equipment, like bulldozers and forklifts, "when imported from trade deal countries that are entitled to such treatment," the White House said.The proclamation also allows foreign companies to qualify for a 10% duty rate if their capital equipment includes at least 85% US melted and poured or smelted and cast steel or aluminum by weight, the White House said.The tariff changes will last until Dec. 31, 2027, to "spur near-term investments," the White House said.Price: $565.43, Change: $+23.00, Percent Change: +4.24%